Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
49.6 EUR | -0.80% | +2.89% | -32.70% |
01:30pm | Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants | CI |
06-11 | Cytokinetics Insider Sold Shares Worth $413,106, According to a Recent SEC Filing | MT |
End-of-day quotes
Compared values
Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
---|---|---|---|---|---|---|---|---|---|---|---|
CYTOKINETICS, INCORPORATED | Bio Therapeutic Drugs | -0.40% | +2.89% | -32.70% | +57.59% | +488.24% | 6.27B | - | - | - |
- Stock Market
- Equities
- CYTK Stock
- KK3A Stock
- Charts Cytokinetics, Incorporated
- Relative Strength Chart